Raymond James Upgrades Dianthus Therapeutics (NASDAQ:DNTH) to Moderate Buy

Raymond James upgraded shares of Dianthus Therapeutics (NASDAQ:DNTH - Free Report) to a moderate buy rating in a report issued on Thursday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer lifted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a report on Monday, November 11th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $46.43.

Dianthus Therapeutics Price Performance

DNTH stock traded up $0.31 during mid-day trading on Thursday, reaching $23.81. The company had a trading volume of 113,847 shares, compared to its average volume of 205,775. The firm has a 50 day moving average of $26.09 and a 200 day moving average of $26.54. Dianthus Therapeutics has a 12 month low of $6.58 and a 12 month high of $33.77. The company has a market capitalization of $704.78 million, a PE ratio of -9.52 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. Analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Quest Partners LLC raised its position in shares of Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company's stock valued at $31,000 after purchasing an additional 1,124 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at $112,000. The Manufacturers Life Insurance Company purchased a new position in Dianthus Therapeutics in the 2nd quarter worth $236,000. Fred Alger Management LLC lifted its position in Dianthus Therapeutics by 52.5% during the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company's stock worth $264,000 after acquiring an additional 3,316 shares during the period. Finally, WINTON GROUP Ltd purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at about $265,000. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.